UBS Upgrades Medivation (MDVN) to Buy Ahead of Ph3 PREVAIL

July 17, 2013 8:03 AM EDT Send to a Friend
Get Alerts MDVN Hot Sheet
Price: $101.87 +2.48%

Rating Summary:
    20 Buy, 5 Hold, 2 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 24 | Down: 28 | New: 14
Trade MDVN Now!
Join SI Premium – FREE
UBS upgraded Medivation (NASDAQ: MDVN) from Neutral to Buy with a price target of $74.00 (from $59.00). Analyst Matthew Roden expects positive result from PREVAIL phase-3 study.

"Despite our favorable view on the ph3 PREVAIL study (data 2H13e), we initiated Neutral on MDVN last December because we felt the risk-reward was balanced ahead of the hormonenaïve data and Xtandi quarterly prints. Our updated analysis suggests that despite availability of Zytiga and Xtandi for some patients after progression (the principal risk to a survival [OS] benefit, in our view), the data will suggest a greater magnitude of OS benefit than Zytiga (the principal debate)," said Roden.

"We view PREVAIL as Medivation’s opportunity to differentiate Xtandi vis-à-vis Zytiga’s ph3 ‘302 study. While we see low-probability risk to MDVN shares if the result is similar to Zytiga, we think a statistically-significant result in PREVAIL would eliminate binary risk, thereby making MDVN more broadly ownable," he added.

For an analyst ratings summary and ratings history on Medivation (NASDAQ: MDVN) click here. For more ratings news on Medivation click here.

Shares of Medivation closed at $55.50 yesterday.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Analyst EPS View, Hot Upgrades, Upgrades

Related Entities

UBS

Add Your Comment